TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
News|Slideshows|May 15, 2025
ACOG 2025: Menopause and Vasomotor Symptoms Preview
Author(s)Sydney Jennings
Fact checked by: Grace Halsey
A preview of sessions covering menopause and vasomotor symptoms during ACOG 2025 in Minneapolis, MN.
Advertisement
The preview slideshow spotlights 6 high-yield sessions (times, faculty, and key takeaways) to help clinicians map their agenda and stay ahead of the “hot-topic” advances reshaping menopause care.
Advertisement
Related to this article
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.
TMS 2026: Post hoc OASIS 1 and 2 data show more women on elinzanetant reported improvement across all 8 PROMIS sleep disturbance items vs placebo at week 12.
In a pilot study of 20 midlife women with vasomotor symptoms, an AI-enabled VR program delivering CBT showed early feasibility and acceptability.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
2
Menopause Diagnoses Documented in Just 7.8% of Midlife Women's Outpatient Visits, Study Finds
3
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
4
JoAnn Pinkerton, MD, on Counseling Patients Starting Elinzanetant for VMS
5